Cutler Group LP Ocugen, Inc. Transaction History

Cutler Group LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$1.11 - $1.87 $1,887 - $3,179	1,700 Added 94.44%	3,500 $4,000
Q2 2022 Aug 04, 2022	SELL	$1.83 - $3.45 $10,980 - $20,700	-6,000 Reduced 76.92%	1,800 $4,000
Q1 2022 Apr 14, 2022	BUY	$2.34 - $4.72 $2,808 - $5,664	1,200 Added 18.18%	7,800 $25,000
Q4 2021 Jan 18, 2022	BUY	$4.38 - $15.67 $16,206 - $57,979	3,700 Added 127.59%	6,600 $30,000
Q3 2021 Oct 26, 2021	SELL	$6.36 - $8.51 $30,044 - $40,201	-4,724 Reduced 61.96%	2,900 $20,000
Q2 2021 Jul 19, 2021	SELL	$5.52 - $15.68 $9,450 - $26,844	-1,712 Reduced 18.34%	7,624 $61,000
Q1 2021 Apr 26, 2021	BUY	$1.66 - $15.81 $15,497 - $147,602	9,336 New	9,336 $63,000

124

78.3M

535K

523K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $167M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.